Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI Net Margin % is -219.50% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Verici Dx ranks worse than 84.24% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Verici Dx's Net Income for the
six
months ended in Dec. 2025 was £-2.87 Mil. Verici Dx's Revenue for the
six
months ended in Dec. 2025 was £1.31 Mil. Therefore, Verici Dx's net margin for the quarter that ended in Dec. 2025 was -219.50%.
The historical rank and industry rank for Verici Dx's Net Margin % or its related term are showing as below:
LSE:VRCI'
s Net Margin % Range Over the Past 10 Years
Min: -862.5 Med: -189.22 Max: -175.92
Current: -189.4
LSE:VRCI's Net Margin % is ranked worse than 84.24% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.81
vs LSE:VRCI: -189.40
Verici Dx (LSE:VRCI) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Verici Dx Net Margin % Related Terms
Verici Dx Net Margin % Historical Data
* Premium members only.
The historical data trend for Verici Dx's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VRCI vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Verici Dx's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Net Margin % distribution charts can be found below:
* The bar in red indicates where Verici Dx's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (LSE:VRCI) has a Net Margin % of -219.50% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #171 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 84.2%.
Is Verici Dx's Net Margin % too high?
Verici Dx's current Net Margin % is -219.50%. Based on the distribution chart, Verici Dx ranks #171 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #171 out of 203 companies for Net Margin %. This places Verici Dx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Verici Dx and its competitors. Verici Dx's current Net Margin % is -219.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current Net Margin % of -219.50%. The current Net Margin % is -219.50%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current Net Margin % is -219.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
